# Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

> **NCT07284927** · PHASE1 · RECRUITING · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** LV009 Injection

## Key facts

- **NCT ID:** NCT07284927
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2026-12-03
- **Final completion:** 2027-12-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284927, "Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07284927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*